Ratings Trulieve Cannabis Corp. OTC Markets

Equities

TCNNF

CA89788C1041

Market Closed - OTC Markets Other stock markets 03:59:27 2024-07-15 pm EDT			5-day change	1st Jan Change
10 ^USD	0.00%		+7.99%	+91.94%

Jul. 10	Trulieve Cannabis to Open Medical Cannabis Dispensary in Gulf Breeze, Florida	MT
Jul. 10	Trulieve Cannabis Corp. Announces the Opening of A New Medical Cannabis Dispensary in Gulf Breeze, Florida	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company is in a robust financial situation considering its net cash and margin position.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company has insufficient levels of profitability.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TRULIEVE CANNABIS CORP.	+91.94%	1.88B		-
VIREO GROWTH INC.	+90.48%	64.41M	-	-
SIMPLY BETTER BRANDS CORP.	+290.91%	56.83M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes